FDA U.S. FOOD & DRUG ADMINISTRATION

ANDA 091693/S-001

CHANGES BEING EFFECTED IN 30 DAYS
APPROVAL

Dr. Reddy's Laboratories Inc.
U.S. Agent for Dr. Reddy's Laboratories SA
107 College Road East, 2nd Floor
Princeton, NJ 08540
Attention: Srinivasa Rao
Vice President and Head Regulatory Affairs - North America

Received June 20, 2019

Dear Sir:

This is in reference to your supplemental abbreviated new drug application (sANDA) received for review on March 15, 2019, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Ramelteon Tablets, 8 mg.

Reference is also made to any amendments submitted prior to the issuance of this letter.

The sANDA, submitted as "Changes Being Effected in 30 Days," provides for:

- Addition of Dr. Reddy's Laboratories LLC, Shreveport site, as an alternate drug product manufacturing site
- Addition of Pace Analytical Life Sciences as an outside testing site for in-process, release, and stability testing of the drug product
- Addition of Eurofins Lancaster Laboratories as an outside testing site for drug substance particle size testing
- Addition of RD Laboratories and Particle Technology Labs as outside testing sites for excipient testing

We have completed the review of this sANDA, as amended, and it is approved.

REPORTING REQUIREMENTS

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98 and at section 506I of the FD&C Act. The Office of Generic Drugs should be advised of any change in the marketing status of this drug or if this drug will not be available for sale after approval. In particular, under section 506I(b) of the FD&C Act, you are required to notify the Office of Generic Drugs in writing within 180 days from the date of this letter if this drug will not be available for sale within 180 days from the date of approval. As part of such written notification, you must include (1) the identity of the drug by established name and proprietary

name (if any); (2) the ANDA number; (3) the strength of the drug; (4) the date on which the drug will be available for sale, if known; and (5) the reason for not marketing the drug after approval.

ANNUAL FACILITY FEES

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions [1] with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1 of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

Sincerely yours,

{See appended electronic signature page}

For Vincent Sansone, PharmD
Deputy Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research

[1] Some of these provisions were amended by the Generic Drug User Fee Amendments of 2017 (GDUFA II) (Public Law 115-52, Title III).

Heidi
Lee

Digitally signed by Heidi Lee
Date: 6/14/2019 01:15:11PM
GUID: 52795fe90009070673e7de063d080d1f